Literature DB >> 9023046

Integrin expression on cell adhesion function and up-regulation of P125FAK and paxillin in metastatic renal carcinoma cells.

W Jenq1, D R Cooper, G Ramirez.   

Abstract

Integrins from normal human renal cortex epithelial cells (RCEC) and from four renal carcinoma lines (metastatic Caki-1, non-metastatic Caki-2, metastatic ACHN, and non-metastatic 769-P) were compared by immunoprecipitation with specific anti-integrin antibodies. Integrin alpha 2 was present in normal RCEC, but absent in all four tumor lines. There was a 2.0-3.0 fold decrease of alpha 3 and beta 1 in localized tumor lines, and a further 5.0-7.0 fold decrease in metastatic lines over their expression in normal renal cells. No alpha V was detected in Caki-1 cells. The greatest adhesion of all cells occurred in the presence of a stimulatory anti-alpha 3 antibody, mediated by specific matrix proteins employed as substrates, while anti-beta 1 treatment dramatically inhibited cell attachment on collagen IV, plasma fibronectin, laminin and merosin substrates. In addition, the mRNA expression of focal adhesion kinase (p125FAK) and paxillin were up-regulated (2.0-2.5 fold increase) in the metastatic Caki-1 cells over normal RCEC. The alteration of integrin subunits alpha 2, alpha 3, alpha V, beta 1, as well as p125FAK and paxillin may contribute to the pathogenicity and/or metastatic propensity of renal epithelial tumors. The up-regulation of paxillin independently or in concert with p125FAK as shown in this study indicates its significant role as a potential marker of metastasis in renal carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9023046     DOI: 10.3109/03008209609000696

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  9 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value.

Authors:  Lianqing Li; Jing Wang; Lei Gao; Lili Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  Focal adhesion kinase as a cancer therapy target.

Authors:  Vita M Golubovskaya
Journal:  Anticancer Agents Med Chem       Date:  2010-12       Impact factor: 2.505

4.  Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells.

Authors:  Jelena Pribic; Derrick Brazill
Journal:  Cell Signal       Date:  2012-03-28       Impact factor: 4.315

5.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

6.  Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease.

Authors:  Alexander C Mackinnon; Maria Tretiakova; Les Henderson; Rajendra G Mehta; Benjamin C Yan; Loren Joseph; Thomas Krausz; Aliya N Husain; Mary E Reid; Ravi Salgia
Journal:  J Clin Pathol       Date:  2010-11-02       Impact factor: 3.411

7.  EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.

Authors:  Min Chul Cho; Sung Yong Cho; Cheol Yong Yoon; Seung Bae Lee; Cheol Kwak; Hyeon Hoe Kim; Hyeon Jeong
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

8.  Reduced paxillin expression contributes to the antimetastatic effect of 4-hydroxycoumarin on B16-F10 melanoma cells.

Authors:  Marco A Velasco-Velázquez; Nohemí Salinas-Jazmín; Nicandro Mendoza-Patiño; Juan J Mandoki
Journal:  Cancer Cell Int       Date:  2008-05-20       Impact factor: 5.722

9.  The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.

Authors:  Jamie M Aye; Laura L Stafman; Adele P Williams; Evan F Garner; Jerry E Stewart; Joshua C Anderson; Smitha Mruthyunjayappa; Mary G Waldrop; Caroline D Goolsby; Hooper R Markert; Colin Quinn; Raoud Marayati; Elizabeth Mroczek-Musulman; Christopher D Willey; Karina J Yoon; Kimberly F Whelan; Elizabeth A Beierle
Journal:  Oncotarget       Date:  2019-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.